AI in Drug Discovery and Development Challenges

This report examines the integration of artificial intelligence (AI) in drug discovery and development, highlighting current challenges and future opportunities. It begins by outlining the significant headwinds faced by the pharmaceutical industry, including rising costs, prolonged timelines, and high clinical trial failure rates. The report notes that, on average, it takes over 12 years and approximately $2.2 billion to bring a drug to market, with a mere 10% of drug candidates succeeding. The current state of AI is discussed, revealing mixed performance against high expectations, with AI primarily utilized in early discovery phases. The competitive landscape is evolving, with large pharmaceutical companies increasingly conducting AI-related work in-house. The report identifies key opportunities for AI to streamline labor-intensive workflows but also emphasizes challenges such as data availability and integration. Experts suggest that while AI has shown promise, significant hurdles remain, particularly in later stages of drug development, where complexities increase.